Table 4.
Prior therapy comparison between matched MONARCH 1 and real-world chemotherapy cohort
| Patients with any prior therapy | Monarch 1 N = 108 |
Real-world cohort N = 108 |
|---|---|---|
| Chemotherapya, n (%) | 108 (100) | 108 (100) |
| Paclitaxel | 55 (50.9) | 50 (46.3) |
| Capecitabine | 51 (47.2) | 49 (45.4) |
| Docetaxel | 18 (16.7) | 11 (10.2) |
| Cyclophosphamide | 13 (12.0) | 7 (6.5) |
| Gemcitabine | 10 (9.3) | 15 (13.9) |
| Eribulin | 6 (5.6) | 7 (6.5) |
| Otherb | 34 (31.5) | 34 (31.5) |
| Endocrine therapya, n (%) | 91 (84.3) | 92 (85.2) |
| Fulvestrant | 52 (48.1) | 59 (54.6) |
| Exemestane | 45 (41.7) | 42 (38.9) |
| Letrozole | 40 (37.0) | 20 (18.5) |
| Tamoxifen | 29 (26.9) | 12 (11.1) |
| Anastrozole | 19 (17.6) | 22 (20.4) |
| Otherc | 14 (13.0) | 10 (9.3) |
| Targeted therapya, n (%) | 48 (44.4) | 32 (29.6) |
| Everolimus | 29 (26.9) | 32 (29.6) |
| Bevacizumab | 13 (12.0) | 0 |
| Otherd | 13 (12.0) | 1 (0.9) |
| Othera, n (%) | 21 (19.4) | 2 (1.9) |
| Investigational drug | 14 (13.0) | 0 |
| Othere | 10 (9.3) | 2 (1.9) |
N Total number of patients, n number of patients within a specific category
aAny single therapy with > 10% in either arm is listed; all other therapies, except eribulin (included in the table) are combined into ‘other’ in each category
bOther chemotherapy agents include doxorubicin, carboplatin, fluorouracil, vinorelbine, epirubicin, cyclophosphamide w/epirubicin hydrochloride/f, cyclophosphamide w/doxorubicin, methotrexate, mitoxantrone, oxaliplatin, paclitaxel w/carboplatin, cisplatin, doxorubicin pegylated liposomal, and ixabepilone
cOther endocrine therapy regimens include megestrol, abiraterone, bicalutamide, diethylstilbestrol, enzalutamide, gonadorelin, goserelin, leuprorelin, medroxyprogesterone, toremifene, triptorelin, and leuprolide
dOther targeted therapies include dasatinib, ganetespib, taselisib, abexinostat, buparlisib, olaparib, ramucirumab, ridaforolimus, ruxolitinib, veliparib, and cetuximab
eOther other therapies include denosumab, zoledronic acid, fluoxymesterone, prednisolone, leucovorin, and sorafenib